pembrolizumab,pds0101
pds biotech,merck
['keytruda', '$pdsb']
don't forget ph3 design based on pfs and os as primary endpoints.doubling of patient n did not impact the great update on pfs and os vs last asco in 2022.highly favorable vs keytruda and keytruda +chemo.not to speak about the stellar safety profile of $pdsb. ignoring the noise. 
Tweets are just how I see the world and not an investment advice. Do your own dd.